Vivet Therapeutics
Paris, FR · Founded 2016 · 8 known investors
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis. Its pipeline is built on technologies licensed from FIMA at the University of Navarra in Spain.
BiotechHealthtech
Investors · 8
HealthCap✓ verifiedStockholm
Kurma Partners✓ verifiedParis · $162K – $10.8M
Novartis Venture Fund✓ verifiedBasel · $5M – $25M
Roche Venture Fund✓ verifiedBasel · $648K – $3.2M
Ysios Capital✓ verifiedBarcelona · $5.4M – $21.6M
Columbus Venture Partners✓ verifiedValenciavia Jose Mesa · inferred
Eurazeo✓ verifiedParis
Pfizer Venture Investments$5M – $20M
Competitors · 7
by search overlapIpsen13 shared keywordsIpsen is a biopharmaceutical company that develops and commercializes medicines across three therapeutic areas—oncology, rare diseases, and neuroscience—for patients with high unmet medical needs. Its portfolio includes treatments for neuroendocrine tumors and cancers of the kidney, liver, pancreas, thyroid, prostate and breast, as well as rare bone, liver, and neurogenetic disorders and neurological conditions.
Gatsby11 shared keywordsGatsby is an event management platform that sends invitations from partners' actual email accounts and provides customizable registration pages with guest profiles and adaptive forms.
Jefferies11 shared keywordsJefferies is a financial services firm offering investment banking, wealth management, and related capital markets services. The captured page is a multilingual fraud-alert notice warning that impersonators are misusing the Jefferies name to solicit fake investments and jobs.
IO Biotech10 shared keywordsThe page presents a biography of Dr. Dhingra, a medical oncologist and physician-scientist with experience in oncology drug development. It provides no clear description of the company's own products or services.
Kodiak Sciences10 shared keywordsKodiak Sciences is a biotechnology company developing therapeutics for retinal and ophthalmic diseases, including wet AMD, diabetic retinopathy, retinal vein occlusion, and macular edema. Its Antibody Biopolymer Conjugate Drug (ABCD) platform underpins late-phase candidates such as Zenkuda, KSI-501, and KSI-101.
PrecisionLife10 shared keywordsPrecisionLife uses genetic analysis and AI to decode the underlying disease mechanisms of complex chronic diseases beyond oncology, offering diagnostic and prognostic tools (Mechanostics) to stratify patients. It serves healthcare and drug developers by identifying novel therapeutic targets, predicting treatment response, and enriching clinical trials.
Medscape10 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with Vivet Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Vivet Therapeutics do?
- Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis. Its pipeline is built on technologies licensed from FIMA at the University of Navarra in Spain.
- Who are Vivet Therapeutics's investors?
- Vivet Therapeutics's investors include HealthCap, Kurma Partners, Novartis Venture Fund, Roche Venture Fund, Ysios Capital, Columbus Venture Partners, Eurazeo, Pfizer Venture Investments.
- Where is Vivet Therapeutics headquartered?
- Vivet Therapeutics is headquartered in Paris, FR.